Biomarkers for early identification of recurrences in HPV-driven oropharyngeal cancer

Human papillomavirus (HPV)-driven oropharyngeal cancers (OPC) have a good prognosis, yet 20 –25% of patients will recur within 5 years of treatment and a significant portion will die from their disease[1,2]1. After treatment, physical examination and imaging are the basis of current monitoring strategies. However, these modalities are not ideal as the majority of recurrences are diagno sed at a late stage when the likelihood of cure becomes low. This situation calls for the development of new tools to identify patients at increased risk of relapse.
Source: Oral Oncology - Category: Cancer & Oncology Authors: Tags: Review Source Type: research